The Minnesota Department of Health (MDH) says about 3,850 women in Minnesota are living with an ovarian cancer diagnosis and ...

Shares of Verastem Oncology VSTM rallied 40.9% on Tuesday after it announced that the FDA has accepted the new drug ...

An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade ...

FDA officials have set a review date of June 30, 2025, to review avutometinib in combination with defactinib to treat ...

A new international study led by researchers at Karolinska Institutet in Sweden shows that AI-based models can outperform ...

When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under Priority Review for avutometinib, in combination with defactinib, for the treatment of adults with ...

A new international study shows that AI-based models can outperform human experts at identifying ovarian cancer in ultrasound images.

(RTTNews) - Biopharmaceutical company Verastem Oncology (VSTM) Monday said that its treatment for a rare form of ovarian cancer has been given priority review by the Food and Drug Administration.

In a major leap toward more effective cancer treatments ... on high-grade serous ovarian cancer (HGSOC), and the pipeline ...

Given the serious nature of ovarian cancer and the competitive landscape for new treatments, the timeline for the upcoming Phase 3 trial may not be aggressive enough to capitalize on immediate ...